Over the next decade, the way humanity confronts cancer is quietly being rewritten. What was once the frontier of experimental medicine — vaccines and immunotherapies that enlist the body's own defenses — is now entering the mainstream of clinical practice, with market projections showing 36 percent annual growth through 2036. This expansion is not merely commercial; it reflects a deepening scientific understanding of disease and a collective willingness to invest in treatments that work with biology rather than against it. The question now is whether the promise forged in research settings ca